Literature DB >> 10852987

Clinical quality management in rheumatoid arthritis: putting theory into practice. Swiss Clinical Quality Management in Rheumatoid Arthritis.

E Uitz1, J Fransen, T Langenegger, G Stucki.   

Abstract

Clinical quality management (CQM) in rheumatoid arthritis (RA) aims to reduce inflammatory activity and pain in the short term, and damage, and consequently disability, in the long term. Within CQM as used in Switzerland rheumatologists are provided with a measurement feedback system with which they can regularly follow their patients. Inflammatory activity is measured with the Disease Activity Score (DAS28) and the Rheumatoid Arthritis Disease Activity Index questionnaire (RADAI), damage with an X-ray score and disability with the Stanford Health Assessment Questionnaire (HAQ). Feedback is used to optimize therapy, which in the short term allows the activity of the inflammatory process to be adjusted or 'titrated'. In the long term, the therapy result for the individual patient is monitored by the course of disability and damage. In this paper we present a series of cases to illustrate the usefulness of the CQM system in the management of individual RA patients. CQM in RA may be helpful when making decisions about adjustment of treatment, and to document and communicate these decisions based on quantitative data.

Entities:  

Mesh:

Year:  2000        PMID: 10852987     DOI: 10.1093/rheumatology/39.5.542

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  33 in total

1.  Great expectations of modern RA treatment.

Authors:  S Irvine; H C Capell
Journal:  Ann Rheum Dis       Date:  2005-09       Impact factor: 19.103

Review 2.  [Activity-score based therapy in rheumatoid arthritis].

Authors:  K Machold; V Nell; D Aletaha; J Smolen; T Stamm
Journal:  Z Rheumatol       Date:  2006-03       Impact factor: 1.372

3.  The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis.

Authors:  R B Mueller; M Schiff; T Kaegi; A Finckh; S R Haile; H Schulze-Koops; J von Kempis
Journal:  Clin Rheumatol       Date:  2014-07-15       Impact factor: 2.980

Review 4.  Biologics registers in RA: methodological aspects, current role and future applications.

Authors:  Elena Nikiphorou; Maya H Buch; Kimme L Hyrich
Journal:  Nat Rev Rheumatol       Date:  2017-06-01       Impact factor: 20.543

5.  A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries.

Authors:  Jeffrey R Curtis; Archana Jain; Johan Askling; S Louis Bridges; Loreto Carmona; William Dixon; Axel Finckh; Kimme Hyrich; Jeffrey D Greenberg; Joel Kremer; Joachim Listing; Kaleb Michaud; Ted Mikuls; Nancy Shadick; Daniel H Solomon; Michael E Weinblatt; Fred Wolfe; Angela Zink
Journal:  Semin Arthritis Rheum       Date:  2010-08       Impact factor: 5.532

6.  Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

Authors:  A Finckh; J F Simard; C Gabay; P-A Guerne
Journal:  Ann Rheum Dis       Date:  2005-12-08       Impact factor: 19.103

7.  Direct costs related to rheumatoid arthritis: the patient perspective.

Authors:  J L Hülsemann; T Mittendorf; S Merkesdal; S Handelmann; J-M von der Schulenburg; H Zeidler; J Ruof
Journal:  Ann Rheum Dis       Date:  2005-03-30       Impact factor: 19.103

8.  Comparative effectiveness of rheumatoid arthritis therapies.

Authors:  Axel Finckh
Journal:  Curr Rheumatol Rep       Date:  2010-10       Impact factor: 4.592

9.  Managing chronic disease: evidence-based medicine or patient centred medicine?

Authors:  Thea P M Vliet Vlieland
Journal:  Health Care Anal       Date:  2002

10.  Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Authors:  A Finckh; A Ciurea; L Brulhart; B Möller; U A Walker; D Courvoisier; D Kyburz; J Dudler; C Gabay
Journal:  Ann Rheum Dis       Date:  2009-05-04       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.